PGNX News and Press, Progenics Pharmaceuticals Inc. From 02/17/20

Back in October, Lantheus Holdings ( LNTH ) and Progenics Pharmaceuticals ( PGNX ) publicized their agreement for Lantheus to purchase Progenics in an all-stock transaction. Despite some synergies between the companies, it appears a large portion of Progenics’ shareholders are not in ...

NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that three abstracts highlighting PyL TM ( 18 F-DCFPyL), I-1...

NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, issued the following letter to shareholders: Jan...

NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting data from its PSMA AI program h...

The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...

The SPDR S&P 500 Trust's (SPY) rally to new highs has been a boon to big-cap investors, but the Russell 2000 has yet to eclipse its 2018 highs, and that's left small-cap investors envious. Fortunately, small caps' under-performance may not last much longer. Over the past decade, the Russel...

Intra-Cellular Therapies (NASDAQ: ITCI ) +89%   after Caplyta approved by FDA. More news on: Intra-Cellular Therapies, Inc., Cincinnati Bell Inc., Seadrill Limited, Stocks on the move, Read more ...

Progenics Pharmaceuticals (NASDAQ: PGNX ) is up  20%  premarket on announcing positive top line results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyL ( 18 F-DCFPyL) in men with biochemical recurrence of prostate cancer. More news...

- Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance - Company Expects to Submit an NDA to the FDA in the Second Half of 2020 - Conference Call at 8:00 AM Eastern Time NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) ...

NEW YORK, Dec. 22, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call to review the top line re...